CA
NZ
UK
AU
IND
US
…
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Actinogen Medical Ltd is an Australian clinical-stage biopharmaceutical company developing therapies for cognitive impairment and neurodegenerative disorders, principally Xanamem, an oral inhibitor of 11β-HSD1 designed to reduce brain cortisol. Long-term growth may benefit from successful progression through pivotal trials, regulatory approval and potential licensing or collaborations, which could support commercialisation and make the company attractive to investors seeking exposure to novel approaches in Alzheimer’s disease and cognitive decline.
Key risks include clinical and regulatory failure, lack of marketed products, ongoing funding and dilution risk, and strong competition in the neurodegenerative therapeutics sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -28.05M | -14.73M | -22.98M | -10.75M | -9.50M |
| Net income | -15.38M | -14.73M | -13.04M | -10.75M | -9.52M |
| Selling general administrative | 8.67M | 2.03M | 1.73M | 6.57M | 4.56M |
| Selling and marketing expenses | - | 6.10M | 5.50M | - | - |
| Gross profit | -0.42M | 5.49M | 9.93M | - | - |
| Reconciled depreciation | 0.42M | 0.42M | 0.42M | 0.41M | 0.40M |
| Ebit | -28.11M | -15.35M | -13.26M | -10.74M | -9.48M |
| Ebitda | -27.69M | -15.01M | -12.84M | -10.33M | -9.08M |
| Depreciation and amortization | 0.42M | 0.34M | 0.42M | 0.41M | 0.40M |
| Operating income | -28.11M | -14.93M | -12.84M | -10.74M | -9.48M |
| Other operating expenses | 28.11M | 20.42M | 22.77M | 15.87M | 13.17M |
| Interest expense | 0.47M | 0.05M | 0.02M | 0.02M | 0.02M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.50M | 0.69M | 0.29M | 0.37M | 0.04M |
| Net interest income | 0.03M | 0.64M | 0.27M | 0.35M | 0.02M |
| Income tax expense | -12.67M | -5.49M | -9.93M | 4.79M | 0.02M |
| Total revenue | - | 5.49M | 9.93M | 0.37M | 0.04M |
| Total operating expenses | 27.69M | 20.42M | 22.77M | 15.87M | 13.17M |
| Cost of revenue | 0.42M | - | 0.42M | - | - |
| Total other income expense net | 0.06M | 0.20M | -10.14M | 4.77M | -0.02M |
| Net income from continuing ops | -15.38M | -14.73M | -13.04M | -10.75M | -9.50M |
| Net income applicable to common shares | - | -14.73M | -13.04M | -10.75M | -9.50M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 29.56M | 24.48M | 21.31M | 15.21M | 23.31M |
| Intangible assets | 1.47M | 1.78M | - | 2.41M | 2.72M |
| Other current assets | 0.10M | - | 0.11M | - | - |
| Total liab | 8.18M | 6.15M | 1.62M | 1.80M | 1.57M |
| Total stockholder equity | 21.37M | 18.34M | 19.70M | 13.41M | 21.74M |
| Other current liab | 2.20M | - | 0.70M | 0.70M | 0.58M |
| Common stock | 137.91M | - | 100.02M | 78.71M | 76.94M |
| Capital stock | 137.91M | 101.25M | - | 78.71M | 76.94M |
| Retained earnings | -111.85M | -96.47M | -81.74M | -68.69M | -57.94M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 16.73M | 16.50M | 9.45M | 8.46M | 16.37M |
| Cash and equivalents | - | - | - | 7.18M | 12.10M |
| Total current liabilities | 8.10M | 5.96M | 1.36M | 1.80M | 1.48M |
| Current deferred revenue | - | - | - | -0.09M | -0.08M |
| Net debt | -11.95M | - | -9.13M | -8.37M | -16.21M |
| Short term debt | 4.70M | - | 0.06M | 0.09M | 0.08M |
| Short long term debt | 4.61M | 3.01M | - | - | - |
| Short long term debt total | 4.78M | - | 0.32M | 0.09M | 0.17M |
| Other stockholder equity | -19.97M | - | -10.48M | -14.96M | -23.94M |
| Property plant equipment | - | - | - | 0.11M | 0.17M |
| Total current assets | 27.92M | 22.43M | 18.88M | 12.69M | 20.42M |
| Net tangible assets | - | - | - | 11.00M | 19.02M |
| Net receivables | 11.08M | - | 9.32M | 4.23M | 4.05M |
| Accounts payable | 1.20M | 1.93M | 0.60M | 1.10M | 0.90M |
| Accumulated other comprehensive income | 15.28M | - | 11.89M | 3.39M | 2.74M |
| Non currrent assets other | - | - | 2.09M | -2.52M | -2.89M |
| Non current assets total | 1.64M | 2.05M | 2.44M | 2.52M | 2.89M |
| Capital lease obligations | 0.17M | 0.26M | - | 0.09M | 0.17M |
| Long term debt total | - | - | - | 0.00M | 0.09M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.04M | -0.01M | -0.04M | -0.00M |
| Change to liabilities | - | - | - | 0.25M | 0.69M |
| Total cashflows from investing activities | -0.01M | -0.04M | -0.01M | -0.04M | -0.00M |
| Net borrowings | 1.10M | 3.00M | - | -0.08M | -0.07M |
| Total cash from financing activities | 17.80M | 14.65M | 17.95M | 0.82M | 12.42M |
| Change to operating activities | - | - | - | 0.06M | 0.03M |
| Net income | -15.38M | -14.73M | -13.04M | -10.75M | -9.50M |
| Change in cash | 0.23M | 7.05M | 0.99M | -7.91M | 2.95M |
| Begin period cash flow | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| End period cash flow | 16.73M | 16.50M | 9.45M | 8.46M | 16.37M |
| Total cash from operating activities | -17.56M | -7.56M | -16.95M | -8.70M | -9.52M |
| Issuance of capital stock | 17.55M | 12.24M | 19.11M | 0.90M | 13.32M |
| Depreciation | 0.42M | - | 0.42M | 0.41M | 0.40M |
| Change to account receivables | -5.26M | 3.50M | -5.20M | -0.18M | -2.41M |
| Sale purchase of stock | -0.85M | -0.53M | -1.06M | -0.83M | -0.83M |
| Other cashflows from financing activities | -0.07M | -0.06M | -0.09M | 0.75M | -0.07M |
| Change to netincome | - | - | - | 1.52M | 1.27M |
| Capital expenditures | 0.01M | 0.04M | 0.01M | 0.04M | 0.00M |
| Change in working capital | -4.74M | 5.08M | -5.62M | -0.18M | -2.41M |
| Stock based compensation | - | - | 1.31M | 1.52M | 1.29M |
| Other non cash items | 2.14M | -12.64M | 1.29M | 1.65M | -0.42M |
| Free cash flow | -17.57M | -7.59M | -16.96M | -8.73M | -9.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACW Actinogen Medical Ltd |
-0.00 4.65% |
0.04 | - | 25.97 | 13.14 | 7.25 | 218.33 | -9.95 |
| CSL CSL Ltd |
-0.36 0.18% |
202.04 | - | 22.57 | 6.15 | 4.48 | 4.82 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.41 2.91% |
13.67 | 93.87 | 166.67 | 5.37 | 6.37 | 3.85 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
- -% |
23.24 | 154.93 | 36.36 | 42.38 | 7.52 | 31.95 | 160.40 |
| MSB Mesoblast Ltd |
-0.14 6.45% |
2.03 | - | 454.55 | 23.43 | 3.36 | 18.28 | -9.86 |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. | MD, CEO & Director | 1960 |
| Mr. Jeff Carter BFinAdmin, MAppFin | Chief Financial Officer | 1958 |
| Ms. Tamara Miller | Sr. VP of Product Devel. | NA |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Chief Medical Officer | NA |
| Mr. Michael Roberts | Head of Investor Relations & Corp. Communications | NA |
| Ms. Therese Russell | Head of People & Infrastructure | NA |
| Dr. Christian Toouli | Head of Bus. Devel. | NA |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. | 1963 |
| Dr. Dana C. Hilt M.D. | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 1953 |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Head of Clinical Pharmacology & Lead Physician and Depression | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...